Key Points
- Director Eric Sachetta purchased 27,304 Sensus Healthcare shares at an average of $3.54, investing approximately $96,656 and increasing his direct stake by 10.21% to 294,784 shares. He also made four additional purchases between August 24 and 28.
- Sensus Healthcare shares opened at $3.54, with a market capitalization of about $58.3 million and a 52-week range of $2.66 to $5.49. The stock trades below its 50-day average but near its 200-day average.
- Recent quarterly results were weaker than expected: the company reported a $0.53 per-share loss versus a $0.12 consensus loss, while revenue of $2.29 million fell short of the $4.60 million estimate. Analysts nevertheless maintain a “Moderate Buy” consensus with a $5.83 target price.
Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) Director Eric Sachetta acquired 27,304 shares of the company's stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average price of $3.54 per share, with a total value of $96,656.16. Following the acquisition, the director directly owned 294,784 shares of the company's stock, valued at approximately $1,043,535.36. This represents a 10.21% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
Eric Sachetta also recently made the following trade(s):
- On Friday, August 28th, Eric Sachetta bought 37,537 shares of Sensus Healthcare stock. The shares were acquired at an average cost of $3.44 per share, for a total transaction of $129,127.28.
- On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The shares were acquired at an average price of $3.18 per share, for a total transaction of $34,741.50.
- On Wednesday, August 26th, Eric Sachetta bought 9,708 shares of Sensus Healthcare stock. The shares were acquired at an average price of $3.29 per share, for a total transaction of $31,939.32.
- On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, with a total value of $112,765.25.
Sensus Healthcare Stock Up 0.6%
NASDAQ:SRTS opened at $3.54 on Tuesday. The company has a fifty day simple moving average of $3.07 and a two-hundred day simple moving average of $3.51. The company has a market cap of $58.27 million, a price-to-earnings ratio of -3.77 and a beta of 1.10. Sensus Healthcare, Inc. has a 52 week low of $2.66 and a 52 week high of $5.49.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.41). The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $4.60 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.
Institutional Trading of Sensus Healthcare
Large investors have recently bought and sold shares of the business. EP Wealth Advisors LLC purchased a new position in Sensus Healthcare during the 2nd quarter worth $49,000. XTX Topco Ltd purchased a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $77,000. Jane Street Group LLC purchased a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $79,000. Ingalls & Snyder LLC acquired a new stake in shares of Sensus Healthcare during the fourth quarter worth about $219,000. Finally, BlackRock Inc. acquired a new stake in shares of Sensus Healthcare during the second quarter worth about $252,000. Institutional investors and hedge funds own 25.30% of the company's stock.
Wall Street Analysts Forecast Growth
SRTS has been the subject of several analyst reports. Wall Street Zen cut shares of Sensus Healthcare from a "sell" rating to a "strong sell" rating in a report on Saturday, May 9th. Citigroup reaffirmed a "buy" rating on shares of Sensus Healthcare in a report on Friday, May 8th. Lake Street Capital reduced their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Alliance Global Partners reiterated a "buy" rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Finally, Weiss Ratings cut shares of Sensus Healthcare from a "sell (d)" rating to a "sell (d-)" rating in a research report on Tuesday, August 18th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Sensus Healthcare has a consensus rating of "Moderate Buy" and a consensus target price of $5.83.
Check Out Our Latest Stock Report on SRTS
Sensus Healthcare Company Profile
(
Get Free Report)
Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company's SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare's systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company's flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
